Cyprotex is a world renowned preclinical discovery/development contract research organisation with a core focus
in analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties
of potential new drugs.
in analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties
of potential new drugs.
Cloe® Screen: A high quality screening service which includes solubility, PAMPA, MDR1-MDCK permeability, Caco-2 permeability, cytochrome P450 inhibition, metabolic stability, plasma protein binding and hERG automated patch clamp.
Cloe® Select: A bespoke experimental service focusing on later stage ADME and DMPK. It includes cytochrome P450 induction, Ki determination, metabolite profiling and identification, P-gp inhibition and blood to plasma ratio.
Cloe® Predict: Expertise in predictive modelling using PBPK and QSAR techniques. Our proprietary software Cloe® PK predicts in vivo pharmacokinetics from in vitro ADME and physicochemical data.
 |
|
|---|---|
| July 14, 2010 Result of AGM |  |
| July 14, 2010 AGM Statement | |
| July 8, 2010 Cyprotex Extends Cloe® Screen Cytochrome P450 Isoform Identification (Reaction Phenotyping) Service to Include CYP2B6 | |
Request a quotation or
one of our publications.
